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The decision as to the choice of method for immunizing a large
group of individuals against a communicalble disease should depend
upon the following three considerations; namely, the nature and
frequency of reactions, the degree and persistence of the resulting
immunity, and, finally, the cost in materials and time. In our
present study, the intradermal method of immunization against
typhoid is compared with the subcutaneous method with the above
factors in mind. Tuft,6' '7 in 1931, first suggested the intradermal
method to be the one of choice. During the past decade several
authors7' 8, 10 have confirmed Tuft's work and the intmdermal
method has also been used with apparent success in immunizing
against scarlet fever7 and diphtheria.2 However, most of the
immunologic studies were carried out after relatively short intervals
followingtyphoid vaccnations and on groups in the older age range.
It seemed desirable to study a younger group for at least one year.
Materid and methods
Lederle's T.A.B. vaccine was used. This vaccine contains 1,000 million
typhoid, 500 million paratyphoid A, and 500 million paratyphoid B organisms
per cubic centimeter. Forty-four high-grade boys living in one cottage were
chosen for the subcutaneous injections. They varied in age from 6 to 17,
averaging about 10 years of age. They received three injections, 0.5 cc.,
1.0 cc., and 1.0 cc., at weekly intervals. Forty-one girls, living in another
cottage, ranging in age from 7 to 19 and also averaging about 10 years of age,
were selected for the intradermal inoculations. These individuals received
0.05 cc., 0.1 cc., and 0.1 cc. at weekly intervals, respectively.
Blood was drawn from both groups after 50 days, 5 months, and 13
months, respectively, following the last injection. Using the rapid slide agglu-
tination technic described by Welch and Stuart,1' the levels of the somatic
"O" and the flagellar "H" agglutinins were estimated.
Results
Table I summarizes the results of the agglutination tests using
the somatic "O" and the flagellar "H" agglutinogens. As regards
* From the Southbury Training School, Southbury, Connecticut.YALE JOURNAL OF BIOLOGY AND MEDICINE
the "O" agglutinin, it will be noted that the greater percentage of
subjects with the higher titers are in the group vaccinated intrader-
mally. This becomes more evident in the results obtained after 13
months. Thus, at this time, in the intradermal group over three
times as many individuals show a titer of 1: 40 or better as are found
TABLE 1
PRODUCTION OF "0" AND "H,) AGGLUTININS FOLLOWING TAB VACCINATION.
SUBCUTANEOUS VS. INTRADERMAL IMMUNIZATION
Somatic agglutinins ("O") FlageUar agglutinins ("H")
Group Cases 0 20 40 80 160 320 0 20 40 80 160 320
A. 50 days* SO SO % SO SO SO S SO SO SO SO SO
Subcutaneous 443 28 37 26 5 5 0 0 5 16 53 21 5
Intradermal 41 41 27 15 15 2 0 2 0 2 49 25 22
B. 5 months
Subcutaneous 27 48 30 15 7 0 0 4 15 37 41 4 0
Intradermal 31 52 10 22 13 0 3 3 6 10 55 19 6
C. 13 months
Subcutaneous 44 68 21 7 2 2 0 23 36 39 2 0 0
Intradermal 37 41 24 24 1 1 0 0 30 27 21 16 3 3
* Lapse of time since last TAB vaccination.
in the subcutaneous group. While the percentage ofsubjects having
no demonstrable "O" agglutinin is greater in the intradermal group
at the end of 50 days, this percentage is significantly less at the end
of 13 months. The titer of "O" agglutinin demonstrated by the
intradermal group at the end of 50 days is maintained at a fairly
constant level throughout the following year. On the other hand,
in the group inoculated subcutaneously there is a definite tendency
for the titers to fall, so that by the end of 13 months over two-thirds
of those in this group have no demonstrable "O" agglutinin.
Similarly, the group inoculated intradermally shows a signifi-
cantly larger percentage of higher titer values for the "H" agglu-
tinin. However, there is no significant difference between the two
groups as to therapidity in which this agglutinin is no longer demon-
strable. In both groups, the "H" agglutinin is present in the
greater percentage of cases and to a greater degree than is the "O"
agglutinin.
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In Table 2 the data are analyzed so as to indicate in both the
intradermal and subcutaneous groups (a) those individuals that have
both agglutinins present, (b) those individuals that have only the
"O" agglutinin, (c) those that have only the "H" agglutinin
present, and (d) those individuals in whom neither agglutinin is
demonstrable.
TABLE 2
PRODUCTION OF 0 AND H AGGLUTININS IN RESPONSE TO SUBCUTANEOUS
AND INTRADERMAL VACCINATION
50 days* 5 months 13 months
Agglutinins Subcut. Intrad. Subcut. Intrad. Subcut. Intrad.
"O" & "H" 72.1% 58.3% 51.9%7 48.4%7 31.9%7 51.47%
"O" alone 0 0 0 0 0 8.1%
"H" alone 27.9%7 39.2%o 44.47% 48.4% 45.4%7 18.9%D
None 0 2.57% 3.7%7o 3.2% 22.7X% 21.6%0
Total "O" 72.1% 58.37% 51.970 48.4% 31.9%?o 59.5%
Total "H" 1OO.Ogo 97.5%fo 96.3%fo 96.8%o 77.3%o 70.3%b
* Lapse of time since last TAB vaccination.
Of the individuals that have both agglutinins, the subcutaneous
group shows a higher percentage of positive reactors at the end of
50 days, but bythe endof 5 months there nolonger is any significant
difference, and by the end of 13 months the reverse is true. This
apparent difference between the two groups is almost entirely due
to the loss of the "O" agglutinin reactors in the subcutaneous group,
whereas the "O" reactors in the intradermal group remain quite
constant throughout the study.
The presence of the "H" or "O" agglutinin alone is compared
in each group. When one of the two agglutinins is no longer
demonstrable, the "O" agglutinin is the one that is always lost in
the subcutaneous group; the same is true for the intradermal group
with the exception of 3 cases (8.1 per cent) at the end of 13 months.
About 97 per cent of both groups retain at least one of the
agglutinins (the "H" agglutinin) for at least 5 months, but by the
end of 13 months about 22 per cent of each group have lost both
agglutinins. This finding is in agreement with Perry,4 who found
that about 25 per cent of his cases had lost both agglutinins at the
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end of one year. Longfellow and Luippold3 and Siler and Dun-
ham5 found that about 20 per cent of their cases had theoretically
inadequate levels of mouse protection antibodies at from 12 to 18
months after vaccination.
Reactions
Because of the relatively small number of cases, a comparison
of the reactions in the two groups has little statistical significance.
Two children in the group inoculated intradermally had a tempera-
ture of approximately 1000 F., which lasted less than 12 hours, with
associated malaise and marked redness and induration at the site of
inoculation. In the group inoculated subcutaneously, there were
four children that reacted with fever (1000 F. or higher), general
malaise, and pain and swelling at the site of inoculation.
Up to the present time, well over 1000 individuals of all ages
have been vaccinated intradermally. There were only two rela-
tively severe systemic reactions in addition to the cases noted above.
In both cases the site of inoculation showed an area of redness and
induration measuring about 10 cm. in diameter. There was evi-
dence of lymphangitis as well as enlargement and tenderness of the
axillary and epitrochlear glands. Both cases (adults) showed an
elevated temperature, about 1010 F., which subsided in 24 hours.
General malaise with local swelling and pain was noted in somewhat
less than two per cent of the cases. This was almost entirely con-
fined to the adult population, and is a significantly lower incidence
of reactions than result from the usual subcutaneous vaccinations
against typhoid. Van Gelder and Fisher10 recently reported on
approximately 600 children, half of whom received intradermal
inoculations, the remainder, subcutaneous. They found a reaction
rate of 17 per cent in the subcutaneous group as compared to 3 per
cent in the intradermal group.
Discussion
There is no adequately tested procedure for estimating immunity
to typhoid fever. The two methods now in common use, namely,
the determination of specific agglutinin titers and the mouse pro-
tection test must be considered as primarily measures of the presence
of specific humoral antibody responses whose relationship to immu-
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nity is still to be defined. While the mouse protection test would
appear to offer more tangible evidence of a possible immunity than
does the study of agglutinins, it has many practical limitations for
most laboratories. Unfortunately, there are no available data in
the literature comparing simultaneous studies of "O0" and "H"
agglutinin titers with mouse protection tests. It is apparent, there-
fore, that the complete interpretation of data such as were obtained
in this study cannot be offered.
However, the fact that the intradermal method of immunization
can give rise to a greater immunogenic response than does the sub-
cutaneous method is of importance. Our data are in essential
agreement with others in this respect.4' 889 It hasalso been demon-
strated that the intradermal method of immunization gives as good
a response (possibly a better one) in the development of mouse pro-
tective antibodies, both followingrevaccination3i 5 and after the initial
vaccination.8
Finally, it should be noted that the intradermal method requires
but one-tenth the quantity of vaccine usually given by the subcu-
taneous route. The estimated cost of a three-dose course is 1.2
cents for the intradermal method as compared to 12 cents for the
subcutaneous method. In addition, where large numbers are being
vaccinated, much time can be saved with the intradermal method
by using the same syringe and needle, with proper aseptic technic,
for a relatively large number of individuals.
Summary and conclusions
(1) The results of a comparative study of the intradermal and
subcutaneous methods for anti-typhoid vaccination are described.
(2) On the basis of the immunogenic response, the nature and
frequency of reactions, and the cost in materials and time, the intra-
dermal method is believed to be the preferable one.
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